Open-label clinical trial in ovarian tumor at Roswell Park Cancers Institute in Buffalo.

If data are promising, the study may be extended to add more patients.gov, under trial identifier quantity NCT01567891. Both populous city of Wish and Roswell Park Cancer Institute are National Cancer Institute-designated Comprehensive Cancer Centers.. Adaptimmune initiates Phase I/IIa open-label medical trial in individuals with ovarian cancer Today that it has opened up a Phase I/IIa Adaptimmune announced, multiple-site, two-cohort, open-label clinical trial in ovarian tumor at Roswell Park Cancers Institute in Buffalo, N.Y., and City of Wish in Duarte, Calif., and licensed to Adaptimmune then.J.Non-GAAP net income due to 3SBio Inc. In the 4th quarter of 2011 elevated by 34.3 percent to RMB22.3 million , in comparison to non-GAAP net income of RMB16.6 million in the fourth quarter of 2010. GAAP net income attributable to 3SBio Inc. Per ADS on a fully-diluted basis in the 4th one fourth of 2011 was RMB0.99 in comparison to a GAAP net income attributable to 3SBio Inc. Per Advertisements on a fully-diluted basis of RMB0.30 for the fourth quarter of 2010. Non-GAAP net income attributable to 3SBio Inc. Per Advertisements on a fully-diluted basis in the fourth quarter of 2011 was RMB0.99 , compared to non-GAAP net income due to 3SBio Inc. Per Advertisements on a fully-diluted basis of RMB0.74 in the fourth quarter of 2010. Total Year 2011 Business Highlights Operations EPIAO, the Company's flagship injectable recombinant human erythropoietin item, demonstrated strong development with net revenues in 2011 rising 26.7 percent to RMB317.9 million , in comparison to RMB250.9 million in 2010 2010.